In the therapeutic tumour trial, both gp100.2L and 3L induced enhanced survival compared to the controls, indicating that delivery of the gp100 epitope on VLPs can induce a gp100-specific immune response and substantial antitumour immunity. This evidence concerns the gene PMEL and neoplasm.